Birth Control Gel Approved as First No-Hormone Option in Decades
- FDA approves Evofem’s contraceptive gel, Phexxi, for women
- Annual sales estimated to be more than $400 million by 2024
This article is for subscribers only.
A new birth control gel is the first non-hormonal contraceptive to win FDA approval in decades, bringing another option to the $5.4 billion market.
The gel, marketed as Phexxi by Evofem Biosciences Inc., works by making pH levels in the vagina inhospitable to sperm when applied up to an hour before sex.